properties of B12019 and Neulasta at the clinical dose of 6 mg. In the second trial, Cinfa Biotech administered a reduced, 3 mg dose to 96 volunteers to generate PD and immunogenicity data.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback